Insulin secretion inducer, and accelerator for increasing the number of pancreatic beta-cells
AssigneeSaitama Medical University
InventorsHideo Toyoshima, Tomotaka Yokoo, Nobuhiro Yamada
Life of this patent
Estimating the term…
Loading patent…
AssigneeSaitama Medical University
InventorsHideo Toyoshima, Tomotaka Yokoo, Nobuhiro Yamada
Estimating the term…
Disclosed are: an insulin secretion inducer; an insulin secretion-inducing composition; a process for the production of the composition; an accelerator for increasing the number of pancreatic β-cells; a composition for increasing the number of pancreatic β-cells; a process for the production of the composition; and a viral vector for gene therapy. The insulin secretion inducer or the accelerator for increasing the number of pancreatic β-cells comprises a polypeptide having an amino acid sequence encoded by DNA that is known to encode a membrane protein Tm4sf20 (transmembrane 4 L six family member 20) or the like or a fragment of the polypeptide as an active ingredient.
An insulin secretion inducer comprising at least one of the following active ingredients (a) to (f):
(canceled)
6-9. (canceled)
A viral vector for inducing insulin secretion, wherein DNA is integrated as an exogenous gene into a viral vector enabling expression of the exogenous gene, the DNA being DNA having a base sequence as set forth in at least one of SEQ. ID. No. 1, SEQ. ID. No. 4 and SEQ. ID. No. 7, or being DNA capable of hybridizing under stringent conditions with a strand complementary to DNA having the base sequence as set forth in at least one of SEQ. ID. No. 1, SEQ. ID. No. 4 and SEQ. ID. No. 7.
An accelerator for increasing the number of pancreatic β-cells, the accelerator comprising at least one of the following active ingredients (a) to (f):
(canceled)
17-20. (canceled)
A viral vector for increasing the number of pancreatic β-cells, wherein DNA is integrated as an exogenous gene into a viral vector enabling expression of the exogenous gene, the DNA being DNA having a base sequence as set forth in at least one of SEQ. ID. No. 1, SEQ. ID. No. 4 and SEQ. ID. No. 7, or being DNA capable of hybridizing under stringent conditions with a strand complementary to DNA having the base sequence as set forth in at least one of SEQ. ID. No. 1, SEQ. ID. No. 4 and SEQ. ID. No. 7.
A method of treatment for diseases associated with reduction of insulin secretion capability comprising administering an insulin secretion inducer to a subject in need thereof, the inducer including at least one of the following active ingredients (a) to (f):
A method of treatment for diseases associated with reduction or necrosis in pancreatic β-cells comprising administering an accelerator for increasing the number of pancreatic β-cells to a subject in need thereof, the accelerator including at least one of the following active ingredients (a) to (f):
Dependencies are inferred from the claim text.